Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 497

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 497
---
 306,614 Gain on disposal of investments in equity securities    -   38,409   -    7,245 Reversal of expected credit losses   -   1,689,412   -   - Others   13,507   45,898   -   42,093 TOTAL OTHER INCOME   122,951   1,949,522   19,629   466,407                   OPERATING EXPENSES                 Sales and marketing   (125,299)  (1,861,456)  (18,884)  (569,896)Research and development   (47,511)  -   (54,982)  - General and administrative   (194,038)  (679,321)  (171,881)  (134,678)Provision for expected credit losses    -   (883,533)  -   (1,314,427)TOTAL OPERATING EXPENSES   (366,848)  (3,424,310)  (245,747)  (2,019,001)                  LOSS FROM OPERATIONS   (235,144)  (194,020)  (221,750)  (227,464)                  FINANCE COSTS   (11,795)  (9,072)  (5,052)  (8,877)                  LOSS BEFORE TAX   (246,939)  (203,092)  (226,802)  (236,341)                  Tax expense                 Deferred tax   -   12,305   12,269   5,090 Income tax   -   (15,799)  (2,613)  (36,272)Total tax (expense)/credit   -   (3,494)  9,656   (31,182)                  NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS   $(246,939) $(206,586) $(217,146) $(267,523)

 41Table of Contents

Revenue. For the year ended December